Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Fabricio Racca"'
Autor:
José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez, Manuel Ruiz-Borrego, Juan Miguel Cejalvo, Juan de la Haba-Rodriguez, Laia Garrigós, Fabricio Racca, Sonia Servitja, Salvador Blanch, María Gion, Monica Nave, María Fernández-Abad, Alejandro Martinez-Bueno, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Andrea Malfettone, Javier Cortés, Sofía Braga
Publikováno v:
Neuro-Oncology. 25:157-166
Background Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active brain metastases (BMs). DEBBRAH
Autor:
Aleix, Prat, Luis, Paz-Ares, Manel, Juan, Enriqueta, Felip, Elena, Garralda, Blanca, González, Ana, Arance, Juan, Martín-Liberal, Joaquín, Gavilá, Ana, López-González, Juan Miguel, Cejalvo, Yann, Izarzugaza, Kepa, Amillano, Javier García, Corbacho, Cristina, Saura, Fabricio, Racca, Cinta, Hierro, Esther, Sanfeliu, Xavier, Gonzalez, Jordi, Canes, Guillermo, Villacampa, Fernando, Salvador, Tomás, Pascual, Ricard, Mesía, Andrés, Cervantes, Josep, Tabernero
Publikováno v:
Future oncology (London, England).
Improved selection of cancer patients who are most likely to respond to immune checkpoint inhibitors remains an unmet clinical need. Recently, a positive correlation between levels of
Autor:
Timothy A. Yap, Andres Cervantes, Gerald S. Falchook, Manish R. Patel, Dejan Juric, Saiama N. Waqar, Erin L. Schenk, Geoffrey Shapiro, Valentina Boni, Cesar A. Perez, Barbara Burtness, Yana G. Najjar, Fabricio Racca, Katerin Rojas, Kristy Kuplast-Barr, Kristen McEachern, Manoj Samant, Viviana Bozón, Sudha Parasuraman, Melissa Johnson
Publikováno v:
Cancer Research. 83:CT109-CT109
Background: PARP7 is a stress-induced monoART that suppresses the cellular type I interferon (IFN) response following cytosolic nucleic acid sensing. RBN-2397 is a first-in-class PARP7 inhibitor that induces IFN and an adaptive immune response. The t
Autor:
Aleix Prat, Luis Paz-Ares, Manel Juan, Enriqueta Felip, Elena Garralda, Blanca González, Ana Arance, Juan Martín-Liberal, Joaquín Gavilá, Ana López-González, Juan Miguel Cejalvo, Yann Izarzugaza, Kepa Amillano, Javier García Corbacho, Cristina Saura, Fabricio Racca, Cinta Hierro, Esther Sanfeliu, Xavier Gonzalez, Jordi Canes, Guillermo Villacampa, Fernando Salvador, Tomás Pascual, Ricard Mesía, Andrés Cervantes, Josep Tabernero
Publikováno v:
Future Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
FUTURE ONCOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
FUTURE ONCOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Improved selection of cancer patients who are most likely to respond to immune checkpoint inhibitors remains an unmet clinical need. Recently, a positive correlation between levels of PD1 mRNA and clinical outcome in response to PD1 blockade across d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0983624127a29c3daf3b6ec93e2c3fc
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7023
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7023
Publikováno v:
Current Breast Cancer Reports. 11:248-258
To summarize and discuss the available evidence and ongoing efforts in order to establish the efficacy and safety of immunotherapeutic approaches in HER2-positive breast cancer. The introduction into the clinic of anti-HER2–targeted therapies more
Autor:
P. Cortez, M. Nave, Fabricio Racca, Jose Perez-Garcia, J de la Haba, M. Fernández-Abad, Sofia Braga, Santiago González-Santiago, M. Ruiz Borrego, J.M. Cejalvo, M. Galàn Garmaje, Antonio J. Fernández, S. Blanch, L. Lema, J. Cortés, M. Gion, M. Vaz Batista, A. Llombart Cussac, V. Iranzo, Sonia Servitja
Publikováno v:
Annals of Oncology. 32:S509-S510
Autor:
Rajwinder Lehal, Omar Saavedra Santa Gadea, Maria Bobadilla, Fabricio Racca, Jordi Rodon, Elena Garralda, Michael Pascal Bauer, Jose Manuel Perez Garcia, Javier Cortes, Anastasios Stathis, Michele Vigolo, Renata Ferrarotto, Dagmar Hess, Doris Quon, Elena Lopez Miranda, Florian D. Vogl, Ana Vivancos, Oliver Schönborn-Kellenberger, Paolo Nuciforo, Laura Beni
Publikováno v:
Journal of Clinical Oncology. 39:3020-3020
3020 Background: CB-103 selectively inhibits the CSL-NICD interaction leading to down-regulation of CSL-NICD mediated oncogenic pathway activation downstream of NOTCH receptor/ligand signaling, and has shown potent anti-cancer activity as single agen
Autor:
Michalina Marszewska, Stephan Braun, Anna Patrikidou, Raghad Muhsin Abdul-Karim, Mikael Saulay, Damien Pouessel, Frederique Cantero, Yohann Loriot, Arvind Chaudhry, Hyo Jin Lee, Fabricio Racca, Rodryg Ramlau, Jean-Laurent Deville, Alejandro Gonzalez
Publikováno v:
Journal of Clinical Oncology. 39:437-437
437 Background: DZB is an oral small-molecule FGFR1/2/3 kinase inhibitor, which demonstrated antitumor activity in preclinical and clinical studies (in cholangiocarcinoma patients [pts] with FGFR2-driven tumors and in FGFR1-3-driven urothelial cancer
Publikováno v:
Translational Cancer Research. 6:S179-S181
Publikováno v:
International Journal of Molecular Sciences
The unconventional secretion of proteins is generally caused by cellular stress. During the tumorigenesis, tumor cells experience high levels of stress, and the secretion of some theoretically intracellular proteins is activated. Once in the extracel